You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel Nanoligomer-Based Therapeutics for Inflammatory Bowel Disease
SBC: SACHI BIOWORKS, INC. Topic: 300PROJECT SUMMARY—Sachi Bioworks has developed a platform to rapidly generate Nanoligomers, a novel family of nanoparticle-bound, modified nucleic acid oligomers that up- or down-regulate the expression of selected proteins by binding to targeted DNA or mRNA. In preliminary work, Sachi demonstrated the ability to selectively target and alter the expression of immunomodulatory proteins produced by ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Intervention to Help Orient Men to Excel (IN-HOME): A culturally appropriate CHW training program to reduce minority caregiver burden
SBC: KDH Research & Communication, Inc. Topic: 102KDH Research and Communication (KDHRC) proposes to develop and evaluate Intervention to Help Orient Men to Excel (IN-HOME), which will train community health workers (CHW) to support African American and Latino male caregivers of older adults. IN-HOME-trained CHWs will conduct outreach with caregivers who will gain the knowledge and skills to protect their own health and optimize outcomes for the ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Translational Development of a Targeted and Stroma-penetrating Nanoparticle Drug for Pancreatic Cancer Therapy
SBC: MIGRA-THERAPEUTICS LLC Topic: 102Project Summary Low efficiency in drug delivery and aggressive tumor biology are the major causes of resistance to therapy in pancreatic cancer. The presence of a dense fibrous tumor stroma creates a drug delivery barrier and promotes aggressive biology and drug resistance in pancreatic cancer cells. We have developed a targeted stroma penetrating hyaluronic acid nanoparticle carrying SN38, an act ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
A Novel Anti-inflammatory and Anti-oxidant Therapy for Treating Non-healing Diabetic Foot Ulcers
SBC: CERIA THERAPEUTICS INC Topic: 200PROJECT SUMMARYDelayed or impaired wound healing is a serious complication of diabetes, often leading to lower limb ampu- tations. By 2050, 1 in 3 Americans will develop diabetes, and up to 34% of diabetic patients will develop a diabetic foot ulcer (DFU) in their lifetime. Standard of care for DFUs includes debridement, infection control, maintaining a moist wound environment, and pressure offloa ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Harnessing Coded Ptychography to Deliver AI-powered Evaluation of Unstained Lung Biopsies at the Point-Of-Care
SBC: PATHWARE INC. Topic: NCIThe parent Phase I SBIR grant aims to analyze quantitative phase imaging of lung FNAs using coded ptychography microscopy captured at different wavelengths of light (Specific Aim #1), and demonstrate that Al can correctly detect cells on unstained phase images (Specific Aim #2). Engaging the supplementee, Arianna Pryor, to directly support specific aim #2 is expected to allow us to pursue a more d ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Targeting GPR146 for the Treatment of Homozygous Familial Hypercholesterolemia
SBC: Vesicle Therapeutics Inc. Topic: NHLBIProject Summary Vesicle Therapeutics Inc aims to develop and commercialize a new therapy for homozygous familial hypercholesterolemia (hoFH). A majority of hoFH is caused by mutations in both alleles of the gene encoding the LDL receptor (LDLR). Since the efficacy of both statins and PCSK9 antibody therapies largely depends on functional LDL receptors, patients with hoFH show limited responses to ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
SSW Works: A Virtual Learning Environment for Occupational Skin Cancer Prevention
SBC: KLEIN BUENDEL, INC. Topic: 102Americans who work outdoors are exposed to an extreme amount of solar ultraviolet radiation (UV) over a lifetime that substantially increases their risk for developing skin cancer. Annually, skin cancer is diagnosed in over 3.5 million U.S. adults, melanoma kills nearly 7,000 Americans, and treatment costs at least $8 billion. The U.S. Surgeon General has identified occupational sun safety as a na ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
WayToServe Plus: In-service Professional Development Component to Improve Responsible Alcohol Service
SBC: KLEIN BUENDEL, INC. Topic: 400Among the interventions targeting driving while intoxicated (DWI) by alcohol, Responsible Beverage Service (RBS) training of alcohol servers has shown promise. RBS training is currently required or incentivized by 36 U.S. states and California will require it starting in 2022. Our team has shown that an online RBS training, named WayToServe®, was effective in two randomized trials. These results ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel product for skin decontamination after exposure to chemical warfare agents
SBC: ARMIS BIOPHARMA, INC. Topic: 105ABSTRACT With the increasing threat of terrorism, the development of countermeasures for the event of a chemical attack on civilians has become a high priority. Mass casualty events in which chemical warfare agents (CWA) would be employed in an attack on a civilian population, are a concrete risk. Because of significant differences between members of the military and civilians, existing countermea ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Next Generation Autologous TIL Cancer Therapy: Development of GMP manufacturing process
SBC: TRAMPOLINE PHARMA, INC. Topic: 102The overall goal of this Phase II SBIR grant proposal is to research and develop the GMP manufacturing process for next-generation tumor infiltrating lymphocyte (TIL) cancer therapeutic for solid tumors. In clinical trials, TIL-based immunotherapies have demonstrated tumor regression and increased survival rates against different cancer types. Despite these encouraging clinical results, durable an ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health